Literature DB >> 31184507

A Novel AAV-mediated Gene Delivery System Corrects CFTR Function in Pigs.

Ashley L Cooney1,2,3, Ian M Thornell2,3,4, Brajesh K Singh1,2,3, Viral S Shah2,3,4, David A Stoltz2,3,4, Paul B McCray1,2,3, Joseph Zabner2,3,4, Patrick L Sinn1,2,3.   

Abstract

Cystic fibrosis is an autosomal-recessive disease that is caused by a mutant CFTR (cystic fibrosis transmembrane conductance regulator) gene and is characterized by chronic bacterial lung infections and inflammation. Complementation with functional CFTR normalizes anion transport across the airway surface. Adeno-associated virus (AAV) is a useful vector for gene therapy because of its low immunogenicity and ability to persist for months to years. However, because its episomal expression may decrease after cell division, readministration of the AAV vector may be required. To overcome this, we designed an integrating AAV-based CFTR-expressing vector, termed piggyBac (PB)/AAV, carrying CFTR flanked by the terminal repeats of the piggyBac transposon. With codelivery of the piggyBac transposase, PB/AAV can integrate into the host genome. Because of the packaging constraints of AAV, careful consideration was required to ensure that the vector would package and express its CFTR cDNA cargo. In this short-term study, PB/AAV-CFTR was aerosolized to the airways of CF pigs in the absence of the transposase. Two weeks later, transepithelial Cl- current was restored in freshly excised tracheal and bronchial tissue. Additionally, we observed an increase in tracheal airway surface liquid pH and bacterial killing in comparison with untreated CF pigs. Airway surface liquid from primary airway cells cultured from treated CF pigs exhibited increased pH correlating with decreased viscosity. Together, these results show that complementing CFTR in CF pigs with PB/AAV rescues the anion transport defect in a large-animal CF model. Delivery of this integrating viral vector system to airway progenitor cells could lead to persistent, life-long expression in vivo.

Entities:  

Keywords:  CFTR; adeno-associated virus; cystic fibrosis; gene therapy; piggyBac transposon

Mesh:

Substances:

Year:  2019        PMID: 31184507      PMCID: PMC6890402          DOI: 10.1165/rcmb.2019-0006OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  56 in total

1.  PiggyBac transposon-mediated gene transfer in human cells.

Authors:  Matthew H Wilson; Craig J Coates; Alfred L George
Journal:  Mol Ther       Date:  2007-01       Impact factor: 11.454

2.  Directed evolution of adeno-associated virus to an infectious respiratory virus.

Authors:  Katherine J D A Excoffon; James T Koerber; David D Dickey; Matthew Murtha; Shaf Keshavjee; Brian K Kaspar; Joseph Zabner; David V Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

3.  In vivo model of adeno-associated virus vector persistence and rescue.

Authors:  S A Afione; C K Conrad; W G Kearns; S Chunduru; R Adams; T C Reynolds; W B Guggino; G R Cutting; B J Carter; T R Flotte
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

5.  A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

Authors:  Jerry R Mendell; Zarife Sahenk; Vinod Malik; Ana M Gomez; Kevin M Flanigan; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Eric Meadows; Sarah Lewis; Lyndsey Braun; Kim Shontz; Maria Rouhana; Kelly Reed Clark; Xiomara Q Rosales; Samiah Al-Zaidy; Alessandra Govoni; Louise R Rodino-Klapac; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-17       Impact factor: 11.454

6.  Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers.

Authors:  Ziying Yan; Xingshen Sun; Zehua Feng; Guiying Li; John T Fisher; Zoe A Stewart; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2015-04-20       Impact factor: 5.695

7.  AAV serotype 2 vectors preferentially integrate into active genes in mice.

Authors:  Hiroyuki Nakai; Eugenio Montini; Sally Fuess; Theresa A Storm; Markus Grompe; Mark A Kay
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

8.  Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

Authors:  Richard B Moss; David Rodman; L Terry Spencer; Moira L Aitken; Pamela L Zeitlin; David Waltz; Carlos Milla; Alan S Brody; John P Clancy; Bonnie Ramsey; Nicole Hamblett; Alison E Heald
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

9.  Lentiviral-mediated phenotypic correction of cystic fibrosis pigs.

Authors:  Ashley L Cooney; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Mallory R Stroik; Linda S Powers; Nick D Gansemer; David K Meyerholz; Michael J Welsh; David A Stoltz; Patrick L Sinn; Paul B McCray
Journal:  JCI Insight       Date:  2016-09-08

10.  DNA transposition by protein transduction of the piggyBac transposase from lentiviral Gag precursors.

Authors:  Yujia Cai; Rasmus O Bak; Louise Bechmann Krogh; Nicklas H Staunstrup; Brian Moldt; Thomas J Corydon; Lisbeth Dahl Schrøder; Jacob Giehm Mikkelsen
Journal:  Nucleic Acids Res       Date:  2013-11-21       Impact factor: 16.971

View more
  19 in total

1.  Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.

Authors:  Christian M Brommel; Ashley L Cooney; Patrick L Sinn
Journal:  Hum Gene Ther       Date:  2020-08-21       Impact factor: 5.695

2.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

3.  Highly Efficient Gene Editing of Cystic Fibrosis Patient-Derived Airway Basal Cells Results in Functional CFTR Correction.

Authors:  Shingo Suzuki; Ana M Crane; Varada Anirudhan; Cristina Barillà; Nadine Matthias; Scott H Randell; Andras Rab; Eric J Sorscher; Jenny L Kerschner; Shiyi Yin; Ann Harris; Matthew Mendel; Kenneth Kim; Lei Zhang; Anthony Conway; Brian R Davis
Journal:  Mol Ther       Date:  2020-04-29       Impact factor: 11.454

4.  Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells.

Authors:  Chiara De Santi; Elena Fernández Fernández; Rachel Gaul; Sebastian Vencken; Arlene Glasgow; Irene K Oglesby; Killian Hurley; Finn Hawkins; Nilay Mitash; Fangping Mu; Rana Raoof; David C Henshall; Meritxell B Cutrona; Jeremy C Simpson; Brian J Harvey; Barry Linnane; Paul McNally; Sally Ann Cryan; Ronan MacLoughlin; Agnieszka Swiatecka-Urban; Catherine M Greene
Journal:  Mol Ther       Date:  2020-02-06       Impact factor: 11.454

5.  Transduction of Surface and Basal Cells in Rhesus Macaque Lung Following Repeat Dosing with AAV1CFTR.

Authors:  William B Guggino; Murali K Yanda; Cristina V Cebotaru; Liudmila Cebotaru
Journal:  Hum Gene Ther       Date:  2020-09       Impact factor: 5.695

6.  Targeted Phage Display-based Pulmonary Vaccination in Mice and Non-human Primates.

Authors:  Daniela I Staquicini; E Magda Barbu; Rachel L Zemans; Beth K Dray; Fernanda I Staquicini; Prashant Dogra; Marina Cardó-Vila; Cindy K Miranti; Wallace B Baze; Luisa L Villa; Jorge Kalil; Geetanjali Sharma; Eric R Prossnitz; Zhihui Wang; Vittorio Cristini; Richard L Sidman; Andrew R Berman; Reynold A Panettieri; Rubin M Tuder; Renata Pasqualini; Wadih Arap
Journal:  Med (N Y)       Date:  2020-12-10

Review 7.  Tissue and cell-type-specific transduction using rAAV vectors in lung diseases.

Authors:  Konstantin Kochergin-Nikitsky; Lyubava Belova; Alexander Lavrov; Svetlana Smirnikhina
Journal:  J Mol Med (Berl)       Date:  2021-05-21       Impact factor: 4.599

8.  Update in Pediatrics 2020.

Authors:  Erick Forno; Steven H Abman; Jagdev Singh; Mary E Robbins; Hiran Selvadurai; Paul T Schumacker; Paul D Robinson
Journal:  Am J Respir Crit Care Med       Date:  2021-08-01       Impact factor: 30.528

Review 9.  Contemporary Transposon Tools: A Review and Guide through Mechanisms and Applications of Sleeping Beauty, piggyBac and Tol2 for Genome Engineering.

Authors:  Nicolás Sandoval-Villegas; Wasifa Nurieva; Maximilian Amberger; Zoltán Ivics
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

Review 10.  New Therapies to Correct the Cystic Fibrosis Basic Defect.

Authors:  Christelle Bergeron; André M Cantin
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.